Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 30 Neoplasms 11 Thyroid Neoplasms 7 Thyroid Carcinoma, Anaplastic 6 Brain Neoplasms 6 Multiple Myeloma 4 Glioma 4 Colorectal Neoplasms 4 Hematologic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Thyroid Cancer, Papillary 2 Skin Neoplasms 2 Neoplasm Metastasis 2 Lymphoma 2 Glioblastoma 2 Astrocytoma 2 Ameloblastoma 2 Adenocarcinoma, Follicular 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Rectal Neoplasms 1 Rare Malignant Neoplasm 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1

Interventions

trametinib 1 pegfilgrastim 1 ofatumumab 1 dabrafenib 1 Lenalidomide 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Doxorubicin 1 Docetaxel 1 Daptomycin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fever × dabrafenib × Clear all

NCT01972347 2025-12-16

Neo Combi

Melanoma Institute Australia

Phase 2 Active not recruiting

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡